Roche's Genentech deepens its oncology pipeline bets by paying Astex $25M upfront (up to $490M+ milestones) for early breast cancer compounds.
July 6, 2026 10:53 AM EDT
DealsPharma
Roche's $25M Astex deal is small money upfront, but a big signal for breast cancer goals
Elizabeth Cairns
Senior biopharma journalist
Antares Therapeutics inks $105M upfront deal with Novartis to discover small molecules against undruggable cancer targets, with…
Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than…
(Bloomberg) -- Roche Holding AG agreed to pay Nurix Therapeutics Inc. as much as $2.3 billion for rights to an experimental…
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies
Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers.
Biotech's bull market, Vertex's gene therapy expansion, and more news from The Readout
Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B
